Evidence map›Paper›PMID 41860447›Full record

ArticleChemistryOpen2026

Dual Inhibition of COX-2/5-LOX Through Novel Hybrids of NSAIDs and Peptides: Insights from Molecular Dynamics Simulation and Per-Residue Decomposition.

J Carlos Jiménez-Cruz, Ramón Guzmán-Mejía, Pedro Navarro-Santos, Hugo A García-Gutiérrez, Julio C Ontiveros-Rodríguez, Rafael Herrera-Bucio, Verónica Cortés-Muñoz, Judit A Aviña-Verduzco

Abstract read
In one paragraph

Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

J Carlos Jiménez-CruzSecretaría de Ciencia, Humanidades, Tecnología e Innovación-Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico.ORCID 0000-0002-6527-9204
Ramón Guzmán-MejíaInstituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, México.ORCID 0000-0001-6703-9995
Pedro Navarro-SantosSecretaría de Ciencia, Humanidades, Tecnología e Innovación-Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico.ORCID 0000-0001-8370-1651
Hugo A García-GutiérrezInstituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, México.ORCID 0000-0003-2841-0135
Julio C Ontiveros-RodríguezSecretaría de Ciencia, Humanidades, Tecnología e Innovación-Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico.ORCID 0000-0002-1780-1854
Rafael Herrera-BucioSecretaría de Ciencia, Humanidades, Tecnología e Innovación-Instituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico.ORCID 0000-0002-6147-4352
Verónica Cortés-MuñozInstituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, México.ORCID 0009-0004-8645-6419
Judit A Aviña-VerduzcoInstituto de Investigaciones Químico Biológicas, Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, México.ORCID 0000-0002-1266-5849

Funding

Consejo Nacional de Ciencia y Tecnología (CONACYT, MX) 252239Consejo Nacional de Ciencia y Tecnología (CONACYT, MX) 294024Coordinación de la Investigación Científica, Universidad Michoacana de San Nicolás de HidalgoSecretaria de Ciencia, Humanidades, Tecnología e Innovación (SECIHTI, MX) IIXM4933
6 · The paper itself

Abstract

The present study describes the synthesis of an analog of the anti-inflammatory drug fenbufen, a compound which has recently attracted of renewed interest in the treatment of chronic degenerative diseases such as cancer and rheumatoid arthritis. The molecule under consideration, 4-(4-methoxyphenyl)-4-oxobutanoic acid, is distinguished from fenbufen by the absence of the biphenyl moiety. This characteristic results in the generation of nontoxic metabolites during biotransformation. The incorporation of aromatic amino acid residues (phenylalanine and tyrosine) led to the modulation of the hybrid NSAID-amino acid and NSAID-peptide derivatives, thereby altering their biological activity and safety profile. The inhibitory activity against the dual cyclooxygenase-2/5-lipoxygenase system was evaluated using molecular docking, free energy calculations, and per-residue decomposition analysis based on molecular dynamics simulations. Compounds containing a tyrosine residue or the Tyr-Phe dipeptide exhibited strong drug-receptor binding affinities and long-term stability during our simulations, in some cases outperforming the reference drugs celecoxib and zileuton. The values of the free energy (ΔG) obtained through the Boltzmann equation demonstrated a strong correlation with the energy decomposition data, particularly for the lead compounds, which exhibited stabilizing interactions with the heme prosthetic group and the Fe

Indexed as

Anti-Inflammatory Agents, Non-SteroidalArachidonate 5-LipoxygenaseCyclooxygenase 2Cyclooxygenase 2 InhibitorsLipoxygenase InhibitorsMolecular Dynamics SimulationPeptidesHumansMolecular Docking SimulationThermodynamicsAnti-Inflammatory Agents, Non-SteroidalArachidonate 5-LipoxygenaseCyclooxygenase 2Cyclooxygenase 2 InhibitorsLipoxygenase InhibitorsPeptidesamino acidsCOX‐2/5‐LOXhybridMMPBSANSAID

Identifiers

PMID41860447
PMCPMC13098134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.